Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.216018-58-5,[2,2′:6′,2”-Terpyridine]-4,4′,4”-tricarboxylic acid,as a common compound, the synthetic route is as follows.,216018-58-5

2,2 ‘: 6’, 2 “-terpyridyl-4,4 ‘, 4” -tricarboxylic acid3.65 g (10.0 mmol) of the compound (manufactured by Tateyama Kasei)Was placed in a 500 mL eggplant flask. continue,2,2 ‘: 6’, 2 “-terpyridyl-4,4 ‘, 4” -tricarboxylic acid,5 mL of concentrated sulfuric acid and 300 mL of methanol were added,The resulting solution was heated to reflux for 6 hours.The reaction solution thus obtained was filtered off and the resulting solid was dried under vacuum to give 3.42 g ofTo obtain trimethyl 2,2 ‘: 6’, 2 “-terpyridyl-4,4 ‘, 4” -tricarboxylate.

The synthetic route of 216018-58-5 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; FUJIKURA LIMITED; YAMAGUCHI, TAKESHI; (16 pag.)JP5901496; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15862-19-8,5-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.,15862-19-8

5-bromo-2,2-bipyridine (0.480 g, 2 mmol), 2-methylthiophene (0.401 g, 4 mmol) and KOAc (0.401 g, 4 mmol) in dryDMA (5 mL) were stirred under N2 at 150 C for 20 h in thepresence of Pd(OAc)2 (0.009 g, 2 mol%). After cooling the solution to room temperature, CH2Cl2 (15 mL) and an aqueoussaturated NH4Cl solution (10 mL) were added. The reactionsolution was extracted three times with 15 mL of CH2Cl2, andthe combined organic layers were washed three times with 10mL of water. The solvent was evaporated under reduced pressure, and the crude product was purified by using columnchromatography (silica; 5:1 v/v hexane:EtOAc) to afford compound 1 in 22% yield (111 mg). 1H NMR (CDCl3, 500 MHz): 8.89 (dd, 1H, J = 2.3 and 0.6 Hz, ArH), 8.68 (ddd, 1H, J = 4.7,1.7 and 0.8 Hz, ArH), 8.448.36 (m, 2H, ArH), 7.93 (dd, 1H,J = 8.3 and 2.4 Hz, ArH), 7.82 (td, 1H, J = 7.8 and 1.8 Hz,ArH), 7.30 (ddd, 1H, J = 7.4, 4.8 and 1.1 Hz, ArH), 7.24(d, 1H, J = 3.5 Hz, ArH), 6.826.77 (m, 1H, ArH), 2.54 (s,3H, ArCH3) ppm. HR-MS (ESI+) m/z [M + H]+ calcd. for[C15H13N2S]+ 253.0799; found: 253.0803.

As the paragraph descriping shows that 15862-19-8 is playing an increasingly important role.

Reference：
Article; Kamila, Mritunjoy; Cosquer, Goulven; Breedlove, Brian K.; Yamashita, Masahiro; Bulletin of the Chemical Society of Japan; vol. 90; 5; (2017); p. 595 – 603;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

A solution of (S)-(-)-alpha,alpha-diphenyl-2-pyrrolidinemethanol (240 mg, 0.97 mmol) and 2 M Borane-Dimethylsulfide complex (in THF, 3.4 mL, 6.8 mmol) in dry THF (50 mL) was stirred at rt under N2 for 16 h. A solution of 5-(4-Fluoro-phenyl)-3-oxo-pentanoic acid ethyl ester (2.03 g, 8.57 mmol) in dry THF (20 mL) was then added dropwise at rt over a period of 1 h. The resultant clear solution was stirred at rt for another 35 min and was then cooled to 0 C. in an ice bath. The reaction was quenched by the addition of EtOH (40 mL) and was concentrated under reduced pressure. The residue was taken up with EtOAc (100 mL) and washed successively with H2O (50 mL), 5% NaHCO3 (50 mL), brine (50 mL), and then dried over Na2SO4. Removal of the solvent afforded an oil, which was purified by flush column chromatography on silica gel. The intermediate S-5-(4-Fluoro-phenyl)-3-hydroxy-pentanoic acid ethyl ester was obtained as a colorless oil (1.33 g, 65%). 1H NMR (300 MHz, CDCl3) delta1.25 (t, 3H, J=7), 1.6-1.9 (m, 2H), 2.35-2.50 (m, 2H), 2.60-2.85 (m, 2H), 3.1 (d, 1H, J=5), 3.95-4.05 (m, 1H), 4.1-4.25 (m, 2H), 6.9-7.0 (m, 2H), 7.05-7.2 (m, 2H). ESMS calcd (C13H17FO3): 240.1; found: 241.1 (M+H)+.

22348-32-9, 22348-32-9 (R)-Diphenyl(pyrrolidin-2-yl)methanol 7045371, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Patent; Chen, Shoujun; Sun, Lijun; McCleary, Joel; US2003/60633; (2003); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%., 118949-61-4

The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.118949-61-4,2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

A 20 mL two-necked round-bottomed flask was charged with 69.2 mg (0.23 mmol, MW: 301) of pybox- ip, 87.6mg(0.46 mmol, MW: 190.45) of CuI and 5.0 mL of anhydrous CH2Cl2. A slow stream of nitrogen was passed throughthe system, and the solution was stirred well at room temperature for 24 h by means of magnetic stirring bar. Theexcess CuI was filtered off and the solvent of the filtrate was removed under reduced pressure and a yellow solid wasformed. After drying in vacuum at room temperature, the yield of F was 76.0% (85.4 mg). The structure of thiscatalyst was not confirmed., 118949-61-4

The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937., 22348-32-9

As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1148-79-4, 2,2′:6′,2”-Terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

UO2Cl4?·H2terpy?·H2O (1): A mixture of 1.7 ml (0.2 mmol) UCl4/HCl 0.12 M, 93 mg (0.4 mmol) 2,2???:6???,2???-terpyridine and 3.3 ml (19.8 mmol) HCl 6 M was placed in a Parr vessel and then heated statically at 120 ?°C for 48 h. The resulting yellow product was then filtered off, washed with water and dried at room temperature (reaction yield 77percent). XRD powder pattern indicated that the compound was obtained as a pure phase (Supplementary Information S3).

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Lhoste, Jerome; Henry, Natacha; Loiseau, Thierry; Guyot, Yannick; Abraham, Francis; Polyhedron; vol. 50; 1; (2013); p. 321 – 327;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.216018-58-5,[2,2′:6′,2”-Terpyridine]-4,4′,4”-tricarboxylic acid,as a common compound, the synthetic route is as follows.,216018-58-5

2,2 ‘: 6’, 2 “-terpyridyl-4,4 ‘, 4” -tricarboxylic acid3.65 g (10.0 mmol) of the compound (manufactured by Tateyama Kasei)Was placed in a 500 mL eggplant flask. continue,2,2 ‘: 6’, 2 “-terpyridyl-4,4 ‘, 4” -tricarboxylic acid,5 mL of concentrated sulfuric acid and 300 mL of methanol were added,The resulting solution was heated to reflux for 6 hours.The reaction solution thus obtained was filtered off and the resulting solid was dried under vacuum to give 3.42 g ofTo obtain trimethyl 2,2 ‘: 6’, 2 “-terpyridyl-4,4 ‘, 4” -tricarboxylate.

The synthetic route of 216018-58-5 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; FUJIKURA LIMITED; YAMAGUCHI, TAKESHI; (16 pag.)JP5901496; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, General procedure: A solution of cis-RuII(bpz)2Cl2 (100 mg, 0.205 mmol) and AgNO3 (77 mg, 0.453 mol) in water (25 mL) was heated at reflux for 48 h. After cooling to room temperature, the mixture was filtered through Celite to remove AgCl, and the filtrate was evaporated to dryness. The residue was dissolved in DMF (15 mL) and the solution purged with argon for 15 min. 4,4?-bis(trifluoromethyl)-2,2?-bipyridyl (121 mg, 0.414 mmol) was added and the mixture heated at 100 °C for 24 h under argon. After cooling to room temperature, the solution was evaporated under vacuum to a small volume and diethyl ether (150 mL) added. The precipitate was filtered off and dissolved in a minimum of cold water to which solid NH4PF6 was added. The solid was filtered off and purified by column chromatography as for 1 to give an orange solid. Yield: 73 mg (35percent).

The synthetic route of 71071-46-0 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Coe, Benjamin J.; Peers, Martyn K.; Scrutton, Nigel S.; Polyhedron; vol. 96; (2015); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%., 118949-61-4

The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI